Pharmafile Logo
Pharmafocus logo
Advanced Search

Sarepta Therapeutics

Showing 8 posts of 8 posts found.

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

August 4, 2025
Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …

News

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024
Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics

Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …

News

FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy

May 11, 2023
Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy

The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …

News
ingram_headshot

Sarepta appoints ex-Allergan President as new CEO

June 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sarepta Therapeutics

Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in …

Appointment
stocks1

Weekly Movers: XenoPort, Akari, Bayer…

May 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Sarepta Therapeutics, Stick Market, Stock, Xenoport, finance

Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes through the motions of consolidation. …

Feature
lab

Shares at Sarepta Therapeutics jump after FDA delay in drug approval review

May 26, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment

Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …

News
figures_charts

Shares plunge at Sarepta after negative FDA review on muscle disorder drug

April 21, 2016
Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …

News
shutterstock_38078521

US FDA sets April 25 date to review Sarepta’s DMD drug, shares jump

March 11, 2016
Medical Communications, Research and Development Duchenne Muscular Dystrophy, Eteplirsen, Sarepta Therapeutics, US FDA

Shares in US-based Sarepta Therapeutics (Nasdaq: SRPT) jumped nearly 15% Thursday after the US Food and Drug Administration (FDA) said it …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025